Evidence map›Paper›PMID 33057341›Full record

ArticlePLoS neglected tropical diseases2020

Development and implementation of a strategy for intensified screening for gambiense human African trypanosomiasis in Kongo Central province, DRC.

Crispin Lumbala, Simon Kayembe, Jacquies Makabuza, Pascal Lutumba, Jean-Pierre Van Geertruyden, Paul R Bessell, Joseph Mathu Ndung'u

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in PLoS neglected tropical diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

Crispin LumbalaDirectorate of Disease Control, Ministry of Public Health, Democratic Republic of the Congo.ORCID 0000-0001-8892-1610
Simon KayembeFoundation for Innovative New Diagnostics (FIND), Geneva, Switzerland.
Jacquies MakabuzaProgramme National de Lutte Contre la Trypanosomiase Humaine Africaine, Kinshasa, République Démocratique du Congo.
Pascal LutumbaKinshasa University, Kinshasa, Democratic Republic of the Congo.
Jean-Pierre Van GeertruydenGlobal Health Institute, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
Paul R BessellEpi Interventions, Edinburgh, United Kingdom.
Joseph Mathu Ndung'uFoundation for Innovative New Diagnostics (FIND), Geneva, Switzerland.
FIND · CHMinistry of Public Health · CDProgramme National Multisectoriel de Lutte contre le sida · CDUniversity of Antwerp · BEUniversity of Kinshasa · CD

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Democratic Republic of the Congo (DRC) accounts for the majority of the reported gambiense human African trypanosomiasis (HAT) cases. Kongo Central province in the DRC reports a relatively low, yet steady number of cases, and forms a transboundary focus with Angola and the Republic of Congo. This paper describes an intervention aimed at reducing the case burden in Kongo Central by improving passive case detection, complemented with reactive screening. METHODOLOGY/PRINCIPAL

findingsAt the initiation of this programme in August 2015, 620 health facilities were identified and equipped with Rapid Diagnostic Tests (RDTs) for HAT screening. Of these, 603 (97%) reported use of RDTs, and 584 (94%) that continued to use RDTs to the last quarter of 2016 were used in the analysis going forward. Among all health facilities involved, 23 were equipped to confirm HAT by microscopy, and 4 of the latter were equipped to perform molecular testing with loop-mediated isothermal amplification (LAMP). Patients clinically suspected of HAT were tested with an RDT and those with a positive RDT result were referred to the nearest microscopy facility for confirmatory testing. If RDT positive patients were negative by microscopy, they were tested by LAMP, either on fresh blood or blood that was dried on filter paper and transported to a facility performing LAMP. This network of diagnostic facilities reduced the median distance for a patient to travel to a screening facility from 13.7km when the classical card agglutination test for trypanosomiasis (CATT) was used as a screening test in the past, to 3.4km. As a consequence, passive case detection was improved by between 30% and 130% compared to the period before. Furthermore, the proportion of HAT cases detected in early stage disease by passive screening increased from 27% to 64%. Reactive screening took place in 20 villages where cases were reported by passive screening, and in 45 villages in the neighbourhood of these villages. Reactive screening was responsible for detection of 40% of cases, of which, 90% were in first stage of the disease.

conclusionsThis programme has demonstrated that it is possible to deploy passive screening for HAT at sub-country or country levels in the DRC, and this is made more effective when supplemented with reactive screening. Results and achievements showed an increase in the number of HAT cases detected, the majority of them in early disease, demonstrating that this strategy enables better population coverage and early detection of cases, which is critical in removing the HAT reservoir and interrupting transmission, and could contribute to HAT elimination in regions where it is implemented.

Indexed as

AnimalsDemocratic Republic of the CongoDiagnostic Tests, RoutineHumansMass ScreeningMolecular Diagnostic TechniquesNucleic Acid Amplification TechniquesTrypanosoma brucei gambienseTrypanosomiasis, African

Identifiers

PMID33057341
PMCPMC7591064
OpenAlexW3092696184

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.